Showing 1 - 5 results of 5 for search 'Schellens, J', query time: 0.02s
Refine Results
-
1
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... by Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M
Published 2011Journal article -
2
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... by Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M
Published 2011Journal article -
3
-
4
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... by Boss, D, Schwartz, G, Middleton, MR, Amakye, D, Swaisland, H, Midgley, R, Ranson, M, Danson, S, Calvert, H, Plummer, R, Morris, C, Carvajal, R, Chirieac, L, Schellens, J, Shapiro, G
Published 2010Journal article -
5
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. by Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W
Published 2012Journal article